Advertisement

Cystinuria: Assessing and Managing Risk

  • Nicola T. Sumorok
  • David S. GoldfarbEmail author
Chapter
  • 591 Downloads

Abstract

Cystinuria is a genetic disorder of impaired renal and intestinal transport of cystine and dibasic amino acids. It often presents in childhood and is characterized by the recurrent formation of kidney stones throughout a patient’s lifetime. Patients with cystinuria have an increased risk of the development of chronic kidney disease, even in comparison to other types of stone formers. Due to the significant morbidity associated with both passing kidney stones and undergoing procedures to remove them, the prevention of stone formation is an important focus of treatment. Urinary parameters such as volume, pH, cystine concentration and capacity, and dietary protein and sodium content are all important targets of therapy. A combination of fluid therapy, dietary modifications, alkalinizing agents, and medications such as cystine-binding thiol drugs (tiopronin and d-penicillamine) are considered for each patient in order to attempt to lower the risk of forming cystine stones. We review what is known about the assessment of risk in patients with cystinuria and the management options that are available today or on the horizon.

Keywords

Alkalies Amino acids Cystine Cysteine Genetics Mutation Nephrolithiasis Urolithiasis 

Notes

Acknowledgments

We gratefully acknowledge the support of the Rare Kidney Stone Consortium (U54KD083908), a part of Rare Diseases Clinical Research Network (RDCRN), funded by the NIDDK and National Center For Advancing Translational Sciences (NCATS).

Disclosures

No external funding sources contributed to this study. Goldfarb is a consultant for Takeda, Keryx; a CME speaker for Quintiles, Mission; owner of Ravine Group; and has received funding from NIDDK, ORDR.

References

  1. 1.
    Chillarón J, Font-Llitjós M, Fort J, Zorzano A, Goldfarb DS, Nunes V, et al. Pathophysiology and treatment of cystinuria. Nat Rev Nephrol. 2010 Jul;6:424–34.PubMedCrossRefGoogle Scholar
  2. 2.
    Segal S, Thier SO. Cystinuria. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Editors. The metabolic basis of inherited disease. 6th edn. New York: McGraw-Hill; 1989. pp. 2479–96.Google Scholar
  3. 3.
    Della Strologo L, Pras E, Pontisilli C, Beccia E, Ricci-Barbini V, de Sanctis L, et al. Comparison between SLC3A1 and SLC7A9 cystinuria patients and carriers—a need for a new classification system. J Am Soc Nephrol. 2002 Oct;13(10):2547–53.CrossRefGoogle Scholar
  4. 4.
    Gucev Z, Ristoska-Bojkovska N, Popovska-Jankovic K, Sukarova-Stefanovska E, Tasic V, Plaseska-Karanfilska D, et al. Cystinuria AA (B): Digenic inheritance with three mutations in two cystinuria genes. J Genet. 2011 Apr; 90(1):157–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Nakagawa Y, Asplin JR, Goldfarb DS, Parks JH, Coe FL. Clinical use of cystine supersaturation measurements. J Urol. 2000 Nov;164(5):1481–5.PubMedCrossRefGoogle Scholar
  6. 6.
    Birwé H, Hesse A. High-performance liquid chromatographic determination of urinary cysteine and cystine. Clin Chim Acta. 1991 May;199(1):33–42.PubMedCrossRefGoogle Scholar
  7. 7.
    Coe FL, Clark C, Parks JH, Asplin JR. Solid phase assay of urine cystine supersaturation in the presence of cystine binding drugs. J Urol. 2001 Aug;166(2):688–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Rule AD, Krambeck AE, Lieske JC. Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol. 2011 Aug;6(8):2069–75.PubMedCrossRefGoogle Scholar
  9. 9.
    Worcester EM, Parks JM, Evan AP, Coe FL. Renal function in patients with nephrolithiasis. J Urol. 2006 Aug;176(2):600–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Assimos DG, Leslie SW, Ng C, Streem SB, Hart LJ. The impact of cystinuria on renal function. J Urol. 2002 Jul;168(1):27–30.PubMedCrossRefGoogle Scholar
  11. 11.
    Milliner D, Goldfarb DS, Beara-Lasic L, Edvardsson V, Bergstralh E, Lieske JC, et al. E19 Kidney function in genetic stone formers. Eur Urol Suppl 2013;12(3):36.Google Scholar
  12. 12.
    Dent CE, Senior B. Studies on the treatment of cystinuria. Br J Urol. 1955 Dec;27(4):317–32.PubMedCrossRefGoogle Scholar
  13. 13.
    Goldfarb DS, Coe FC, Asplin JR. Urinary cystine excretion and capacity in patients with cystinuria. Kidney Int. 2006 Mar;69(6):1041–7.PubMedCrossRefGoogle Scholar
  14. 14.
    Rodman JS, Blackburn P, Williams JJ, Brown A, Pospischil MA, Peterson CM. The effect of dietary protein on cystine excretion in patients with cystinuria. Clin Nephrol. 1984 Dec;22(6):273–8.PubMedGoogle Scholar
  15. 15.
    Jaeger P, Portmann L, Saunders A, Rosenberg LE, Their SO. Anticysinuric effects of glutamine and dietary sodium restriction. N Engl J Med. 1986 Oct 30;315(18):1120–3.PubMedCrossRefGoogle Scholar
  16. 16.
    Rodríguez LM, Santos F, Málaga S, Martínez V. Effect of a low sodium diet on urinary elimination of cystine in cystinuric children. Nephron. 1995;71(4):416–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Crawhall JC, Scowen EF, Watts RW. Effect of peniciallamine of cystinuria. Br Med J. 1963 Mar 2;1(5330):588–90.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    McDonald WB, Fellers FX. Penicillamine in the treatment of patients with cystinuria. J Am Med Assoc. 1966;197(6):396–402.CrossRefGoogle Scholar
  19. 19.
    Dahlberg PJ, van den Berg CJ, Kurtz SB, Wilson DM, Smith LH. Clinical features and management of cystinuria. Mayo Clin Proc. 1977 Sep;52(9):533–42.PubMedGoogle Scholar
  20. 20.
    Remien A, Kallistratos G, Burchardt P. Treatment of cystinuria with Thiola. Eur Urol. 1975;1(5):227–8.PubMedGoogle Scholar
  21. 21.
    Barbey F, Joly D, Rieu P, Méjean A, Daudon M, Jungers P. Medical treatment of cystinuria: Critical appraisal of long-term results. J Urol. 2000 May;163(5):1419–23.PubMedCrossRefGoogle Scholar
  22. 22.
    Della Stologo L, Laurenzi C, Legato A, Pastore A. Cystinuria in children and young adults: success in measuring free-cystine urine levels. Pediatr Nephrol. 2007 Nov; 22(11):1869–73.CrossRefGoogle Scholar
  23. 23.
    Jaffe IA. Adverse effects profile of sulhydryl compounds in man. Am J Med. 1986 Mar;80(3):471–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Munday R. Toxicity of thiol and disulfides: Involvement of free radical species. Free Radic Biol Med. 1989;7(6):659–73.PubMedCrossRefGoogle Scholar
  25. 25.
    Pak CY, Fuller C, Sakhaee K, Zerwekh JE, Adams BV. Management of cystine nephrolithiasis with alpha-mercaptopropionylglycine. J Urol. 1986 Nov;136(5):1003–8.PubMedGoogle Scholar
  26. 26.
    Rimer JD, An Z, Zhu Z, Lee MH, Goldfarb DS, Wesson JA, Ward MD. Crystal growth inhibitors for the prevention of L-cystine kidney stones through molecular design. Science. 2010 Oct;330(6002):337–41.PubMedCrossRefGoogle Scholar
  27. 27.
    Moran A., Ben-Nun A, Potashnik R, Bashan N. Renal cells in culture as a model for cystinosis. J Basic Clin Physiol Pharmacol. 1990 Jan–Dec;1(1–4):357–72.PubMedGoogle Scholar
  28. 28.
    Sahota A, Yang M, Shikhel S, et al. Tailored inhibition of cystine stone formation as a therapy for cystinuria. J Inherit Metab Dis. 2012;35(S1):S27.Google Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Medical Service, New York Harbor VA Healthcare SystemNYU Langone Medical CenterNew YorkUSA
  2. 2.Nephrology, New York Harbor VA Healthcare SystemNYU Langone Medical CenterNew YorkUSA

Personalised recommendations